New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
Clinical and Molecular Hepatology
;
: 115-121, 2015.
Article
in English
| WPRIM
| ID: wpr-128622
ABSTRACT
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenylurea Compounds
/
Portal Vein
/
Chemoembolization, Therapeutic
/
Niacinamide
/
Combined Modality Therapy
/
Carcinoma, Hepatocellular
/
Venous Thrombosis
/
Protein Kinase Inhibitors
/
Liver Neoplasms
Type of study:
Practice guideline
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS